ProtoKinetix Updates Testing Progress on Neuronal Retinal Cells in Living Tissue for the Treatment of Macular Degeneration

ST. MARYS, W. Va. PKTX, (BUSINESS WIRE) ProtoKinetix, Incorporated (OTC: PKTX) (the Company or ProtoKinetix ) (www.protokinetix.com) updates its stockholders on the testing of neuronal retinal cells in living tissue at the University of British Columbia (“UBC”) under the guidance of Dr. Gregory-Evans. As explained by Dr. Gregory-Evans, the research program at UBC will be determining whether AAGP™ can help improve the survival of stem cells that are currently being used in human trials to treat retinal blindness. We are doing this
http://bit.ly/2loRrlH